Replicas of «Shares» are available to be removed from the vault as a means to
further global currency circulation.
Not exact matches
Apart from slowing
global demand, export growth is seen crimped by a strong dollar, which so
far this year has strengthened by about 4 percent against the
currencies of the country's main trading partners.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain
global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant
further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign
currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Risks associated with investing in Industrials include the possibility of a worsening in the
global economy, acquisition integration risk, operational issues, failure to introduce to market new and innovative products,
further weakening in the oil market, potential price wars due to any excesses industry capacity, and a sustained rise in the dollar relative to other
currencies.
Apart from slowing
global demand, exports are seen crimped by a strong dollar, which so
far this year has strengthened by about 4 percent against the
currencies of the country's main trading partners.
Central bank weakens
currency further by 1.1 % after previous official cuts that put
global financial markets on edge
The externals have been mixed so
far this week with the
global equity markets in a light round of profit taking selling while the U.S. dollar is correcting to the downside after hitting new highs against most major
currency pairs.
There was a
global impact on
currencies and commodities including Crude Oil as they
further corrected to new lows.
The vote's impact on oil, despite sending
global stocks and
currencies spiralling, has so
far been limited due to expectations of strong summer demand in Asia and the United States, and tightening supplies after a two - year rout.
Similarly, the US dollar's reign as the
global currency was challenged by the introduction of the Euro in 1999 and put under
further strain by the growth in emerging market
currencies.
So, I presented them with comparable dollar returns (see: Comparative dollar returns), which prove that despite the
currency risk,
global investors would have been
far better off owning the Indian subs instead of owning their
global parents.
Gyrating stock values, slumping oil prices, turmoil in foreign
currency markets, predictions of slow growth or even deflation abroad... Suddenly, the outlook for the
global economy and financial markets looks
far different — and much dicier — than just a few months ago.
Australian Treasury in a statement said that this plan would
further «cement Australia's reputation as a
global fintech centre.The Bill will make it easier for new innovative digital
currency businesses to operate in Australia, as the government takes action to boost jobs and wages.»
So
far, the Organization of the Petroleum Exporting Countries (OPEC) is biting into the idea of digital
currency trading for oil commodities — but getting it done viably is still a subject of the
global oil producer's comprehensive study.
Most investors and evangelists have agreed that ingenious technology brought about by digital
currencies may have
far - reaching consequences on cyber security, which is currently one of the biggest challenges facing the
global financial system.
He
further noted that cryptocurrencies like bitcoin, despite the growing interest from the traditional financial industry in blockchain technology, have the potential to take over fiat
currencies and operate as the
global monetary system, given their open structure and decentralized systems.
The yen has been the number one
currency by volume worldwide as
far as bitcoin, and South Korea has taken the third BTC volume position behind the U.S. South Korea also commands the most bitcoin cash (BCH) volume, as the won is over 50 percent of the
global market on any given day.
Nonetheless, the attention on «virtual
currencies far outweighs «its size and magnitude in today's
global economy.»